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Introduction. Pain syndromes affect women after conservative and radical breast oncological procedures. Radiation therapy
influences their development. We report autologous fat grafting therapeutical role in treating chronic pain in irradiated
patients. Materials and Methods. From February 2006 to November 2014, we collect a total of 209 patients who meet the
definition of “Postmastectomy Pain Syndrome” (PMPS) and had undergone mastectomy with axillary dissection (113 patients)
or quadrantectomy (96 patients). Both procedures were followed by radiotherapy. We performed fat grafting following Coleman’s
procedure. Mean amount of adipose tissue injected was 52 cc (±8.9 cc) per breast. Seventy-eight in 209 patients were not treated
surgically and were considered as control group. Data were gathered through preoperative and postoperative VAS questionnaires;
analgesic drug intake was recorded. Results. The follow-up was at 12 months (range 11.7–13.5 months). In 120 treated patients
we detected pain decrease (mean ± SD point reduction, 3.19 ± 2.86). Forty-eight in 59 patients stopped their analgesic drug
therapy. Controls reported a mean ± SD decrease of pain of 1.14 ± 2.72. Results showed that pain decreased significantly in patients
treated (𝑝 < 0.005, Wilcoxon rank-sum test). Conclusion. Our 8-year experience confirms fat grafting effectiveness in decreasing
neuropathic pain.
1. Introduction
Chronic pain affects from 25% to 60% of women submitted to
breast surgery, bothmastectomy and conservative procedures
for oncological reasons, and represents an important clinical
problem involving intra- and postoperative factors [1].
This condition, also named Postmastectomy Pain Syn-
drome (PMPS), is situated in the anterior side of the thorax, in
the axilla, and/or in the upper half of the arm and lasts more
than 3 months after mastectomy or quadrantectomy surgical
procedures [2].
Several risk factors have been advocated to explain the
development of PMPS [3] such as axillary lymph node
dissection [4], chemotherapy agents [5], and postsurgical
complications such as infection, seroma, or hematoma.
Moreover, BMI, age, and physiological status could also
be a predictive factor in postsurgical pain [6].
Beyond all these multifactorial risk factors, radiotherapy
strongly influences the development of PMPS as already
noted by Tasmuth et al. [7].
Medications commonly used to treat nociceptive pain,
such as opioids, have proved to be ineffective for neuropathic
pain and a chronic analgesic therapy is burdened with
complications and high rate of drop-off.
In our experience, autologous fat graft obtained following
Coleman’s technique has proven to be an efficient and safe
procedure in treating the clinical field of breast reconstructive
surgery, providing an important tool for correction of breast
size and shape.
In 2006, our group started treating patients submitted
to mastectomy with axillary dissection and radiotherapy
[8] demonstrating the capability of lipostructure to relieve
chronic pain. We subsequently extended its indications to
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patients submitted to quadrantectomy followed by radiother-
apy [9].
In both groups we observed a significant decrease in pain
after procedure and a reduction of intake of analgesic drug
therapy.
The present review aims to report our experience in
treating chronic pain in irradiated breasts collected after an
8-year experience confirming autologous fat grafting role in
improving pain control in patients affected by PMPS.
2. Patients and Methods
FromFebruary 2006 toNovember 2014, a total of 209 patients
who had undergone mastectomy with axillary dissection
(113 patients) or quadrantectomy (96 patients) came to our
Institution.
Both procedures were followed by radiotherapy for onco-
logical reasons.
We selected patientswho presented severe scar retraction,
radiodystrophy, and chronic pain meeting the definition of
“Postmastectomy Pain Syndrome.”
All patients enlisted had a normal follow-upwith no com-
plications, such as dehiscence, infection, or scar anomalies.
In our study population, we performed autologous fat
grafting following Coleman’s procedure. After routine preop-
erative examination and clinical assessment, patients under-
went liposuction of the subumbilical area under sedation
and local anesthesia. The adipose tissue was harvested from
abdominal subcutaneous fat which is an easy accessible and
abundant reservoir.
The fat graft was injected using 18-gauge angiographic
needle with a snap-on wing (Cordis, a Johnson & Johnson
Company, N. V, Roden, Netherlands) at the dermohypo-
dermal junction in the painful and radiodystrophic scar
areas. The mean amount of adipose tissue injected was 52 cc
(±8.9 cc) per breast. In particular, in patients submitted
to mastectomy, mean amount of adipose tissue was 55 cc
(±9.3 cc) per breast, while in patients submitted to quadran-
tectomy mean value was 39 cc per breast (±5.4 cc).
Seventy-eight in 209 patients with Postmastectomy Pain
Syndrome (41 submitted to mastectomy and 37 to quadran-
tectomy) not treated surgically were considered as a control
group for statistical analysis.
Patients were assigned to control group due to their
refusal to be submitted to surgical procedure, although they
present comparable VAS scores.
During the first visit, a trained research assistant
explained the purpose and methods of this study to each
eligible patient; patients who were willing to participate
signed an informed agreement.
Data were gathered through preoperative and postopera-
tive questionnaires.
Before undergoing the surgical procedure, patients were
required to score their spontaneous pain using a visual
analogue scale ranging from0 to 10; analgesic drug intakewas
also recorded.
During follow-up patients were required to fill out the
same questionnaire and possible modification in analgesic
intake was also accurately recorded.
3. Results
We collected a total of 209 patients; 113 patients were
submitted to mastectomy with axillary dissection, while 96
patients were submitted to quadrantectomy.
In our population we lost a total of nineteen patients in
the follow-up (11 were in case group and 9 were submitted to
mastectomy and 2 were submitted to quadrantectomy, while
8 were controls, 6 who underwent previous mastectomy and
2 who underwent quadrantectomy).
In 120 treated patients we observed a mean VAS before
fat grafting of 7.2 (SD ± 2.1) and a value of 3.3 (SD ± 3.1) after
treatment so that we detected a mean pain decrease of 3.19
(SD ± 2.86).
This effect has been observed since two weeks from the
procedure.
In the treated group a total of 48 patients stopped their
analgesic drug therapy.
In this group mean VAS before fat grafting was 7.7 (±2.7)
and 3.4 (±2.4) after autologous fat grafting; thus the mean
pain decrease was 4.23 (SD ± 2.14).
In the group of patients that continued analgesic therapy
mean VAS before treatment was 7.9 (±1.9), while after treat-
ment mean value was 4.2 (±2.3) with a mean pain decrease of
1.15 (SD ± 2.79).
Control group at first outpatient visit showed ameanVAS
of 6.9 (±2.2), while at follow-up visit they showed ameanVAS
of 5.8 (±1.9) reporting a mean pain decrease of 1.14 (SD ±
2.72).
Statistical analysis of the difference between VAS values
was made before and after treatment in case patients and
at first outpatient visit and at follow-up for controls. In
both groups the follow-up was at 12 months (range 11.7–13.5
months).
Wilcoxon rank-sum test was employed with a level of
significance fixed at 𝑝 < 0.005.
Results showed that pain decreased significantly in
patients with Postmastectomy Pain Syndrome treated with
autologous fat tissue grafting (𝑝 < 0.005), while in control
patients no statistical difference was found (𝑝 > 0.05).
In addition to that we compared VAS values in case
patients before treatment with control patients at first out-
patient visit. Eventually we compared again VAS values in
case patients after treatment with control patients at follow-
up visit. Mann andWhitney test was employed with a level of
significance fixed at 𝑝 < 0.005. While in the first comparison
no statistically significant difference was noted (𝑝 > 0.05), in
the latter a statistical significant difference was observed (𝑝 <
0.005). By performing this test selection bias was excluded.
Results are listed in Table 1.
4. Discussion
Persistent pain as a consequence of surgical treatment has
been established for several common surgical procedures and
represents a clinical problem of great magnitude.
Postmastectomy Pain Syndrome was firstly reported in
the 1970s by Wood [10]. Subsequently the International
Stem Cells International 3
Table 1: Study population description. We differentiate between patients who report PMPS after mastectomy and patients who report PMPS
after quadrantectomy. Analgesic drug intake was recorded for both groups. We report mean VAS values before and after treatment or at
follow-up for controls; mean and median VAS values decrease together with ranges. Analysis of pain before and after treatment in both case
and control patients was performed by means of Wilcoxon test; 𝑝 value significance was fixed at < 0.005. We obtain 𝑝 < 0.005 in cases and
𝑝 > 0.05 in controls. Moreover, by means of Mann and Whitney, we compare VAS values in case patients before treatment with controls
(𝑝 > 0.05) and in case patients after treatment with controls test (𝑝 < 0.005).
PMPS after
mastectomy
Mean VAS
before treatment
PMPS after
quadrantectomy
Mean VAS after
treatment or at
follow-up
Mean VAS
decrease
Median VAS
decrease
Range VAS
decrease
Treated 63 (120 totaltreated patients) 7.2 (±2.1)
57 (120 total
treated patients) 3.3 (±3.1) 3.19 (±2.86) 2.63 −2.1–9.6
Control 35 (70 totalcontrol patients) 6.9 (±2.2)
35 (70 total
control patients) 5.8 (±1.9) 1.14 (±2.72) 1.09 −4.2–6.3
Stop
pharmacologic
therapy
28 (34 total
patients who
assumed
therapy)
7.7 (±2.7)
20 (25 total
patients who
assumed
therapy)
3.4 (±2.4) 4.23 (±2.14) 4.86 −1.6–9.3
Continue
pharmacologic
therapy
6 (34 total
patients who
assumed
therapy)
7.9 (±1.9)
5 (25 total
patients who
assumed
therapy)
4.2 (±2.3) 1.15 (±2.79) 1.0 2.2–2.5
Association for the Study of Pain defined it as a chronic pain
condition with characteristics resembling neuropathic pain.
In patients submitted to quadrantectomy or mastectomy,
it presents common features and for this reason it is con-
sidered as a unique pathological condition characterized
by a dull, burning, and aching sensation exacerbated by
movement of the shoulder girdle [11].
Women affected by PMPS may present signs and symp-
toms such as neck pain, shoulder pain, reduced mobility,
and bad body image, demonstrating a multidimensional
character that affects psychological andphysical aspects of the
patient’s life [12].
Though the exact pathogenesis of PMPS remains unclear,
many etiological theories have been postulated.
During the surgical procedure, dissection of the inter-
costobrachial nerve or damage of axillary nerve pathways
could favor development of chronic pain after mastectomy or
quadrantectomy. For this reason, chronic pain has a greater
rate of occurrence in patients who underwent axillary lymph
node dissection [4].
Chemotherapy agents, such as taxanes, platinum agents,
and vinca alkaloids, are neurotoxic, while endocrine therapy
may induce musculoskeletal pain and arthralgia [5].
Another possible explanation seems to be related to the
scarring process which leads to fibrosis, strong adherence to
the deeper muscular layer, and possible nervous entrapment
which would represent a continuous trigger of nerve excita-
tion. For this reason, postsurgical complications [13, 14] such
as infection, seroma, and hematomamay be potential sources
of the development of persistent pain altering physiological
scarring.
Radiation therapy represents amajor risk factor for devel-
oping of PMPS since it leads to an inflammatory reaction
accompanied by increased production of proinflammatory
cytokines, such as IL-1, IL-6, TNF-alfa, and TGF-beta, and
chemokines such as IL-8 and eotaxin. This inflammatory
reaction can induce peripheral and central sensitization with
a failed nociception system leading to pain augmentation. In
addition to that, radiotherapy stimulates local fibrosis which
could result in a strong adherence to the deeper muscular
layer, sustaining a painful syndrome.
Actually, the mainstay of treatment for PMPS as any form
of neuropathic pain is pharmacological, including the use of
antidepressants [15], antiepileptics, and topical anesthetics,
such as lidocaine patches and opioids. Since a pharmacologic
therapy lasting for a long period is poorly tolerated, non-
pharmacological treatments have been proposed including
psychological approaches, physical therapy, interventional
therapy, spinal cord stimulation, and surgical procedures.
Nevertheless, neuropathic pain remains difficult to treat,
and a combination of therapies may be more effective than
monotherapy.
Our group firstly proposed autologous fat graft as an
effective complementary approach to relieve PMPS. Mov-
ing from the experience of Rigotti et al. [16] who treated
radiotherapy-induced tissue damage, several studies focused
on the capability of fat graft to induce scar tissue architectural
remodelling and regeneration with neoangiogenesis.
In our previous researches, histological proofs [17–19]
have demonstrated how fat grafting could be responsible
for scar remodelling inducing release of fibrotic tissue with
nerve liberation and loose connective regeneration, leading
to increased scar softness.
We have also hypothesized that autologous fat graft
could induce molecular changes in the microenvironment
of posttraumatic scar [20], which is hostile to regeneration
of the nervous system because of intrinsic inhibitory factors
expressed by extracellular matrix, as shown by experimental
model of spinal cord injuries [21], determining pain control as
described in patients affected by Arnold’s Neuralgia [22, 23].
It is possible to hypothesize that fat grafting in PMPS
induces analgesia by inhibition of inflammation. It is relevant
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to notice that mesenchymal stem cells could also down-
regulate radiation therapy induced inflammatory response
as they inhibit production and release of proinflammatory
cytokines, which are the main mediators of radio-induced
tissue damage.
In the present review we report our 8-year experience in
treating Postmastectomy Pain Syndrome with autologous fat
grafting in patients submitted to mastectomy with axillary
dissection and quadrantectomy and radiotherapy.
We considered patients affected as a unique study popu-
lation as they all meet the definition of Postmastectomy Pain
Syndrome.
The main limitation of this study is the fact that we did
not consider the placebo effect to give further strength to our
protocol.
In addition to that our research’s lack of data regarding
patients’ age, BMI, and estrogen status as increasing evidence
seems to correlate these variables to clinical outcome [24].
Comparing data with a wide study population of 120
patients, to our knowledge the largest study population
presented in a scientific report about this condition, we
confirm autologous fat grafting’s promising therapeutic role
in the treatment of Postmastectomy Pain Syndrome.
5. Conclusions
Fat graft has already proven its effectiveness in terms of pain
decrease in the treatment of different forms of neuropathic
pain as a result of its effect of scar entrapment release and
anatomical remodeling.
Because of its safety, efficacy, and optimal tolerability, we
support its adoption as a standard procedure in each Breast
Unit in patients who report chronic pain after breast surgery
especially if previously submitted to radiotherapy.
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